Dr. Philip E. Lammers, MD | Memphis, TN ...

Dr. Philip E. Lammers

Claim this profile

Baptist Memorial Hospital and Cancer Center-Memphis

Studies Breast Cancer
Studies Lung Cancer
20 reported clinical trials
35 drugs studied

About Philip E. Lammers

Education:

  • Completed undergraduate studies at the University of Notre Dame, Notre Dame, IN.
  • Graduated from Indiana University School of Medicine, Indianapolis, IN, in 2006.
  • Residency in Internal Medicine at Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO (2006-2009).
  • Fellowship in Hematology and Medical Oncology at Vanderbilt University Medical Center, Nashville, TN (2010-2013).

Experience:

  • Board-certified in Internal Medicine, Hematology, and Medical Oncology.
  • Serves as Medical Director of Clinical Oncology Research and leads the Clinical Trials Committee at Baptist Cancer Center.
  • Active in Baptist's Mid-South Minority and Underserved NCORP and leads the Multidisciplinary Breast Cancer Clinic.
  • Has secured national grant funding and is a member of the SWOG Breast Cancer Committee.
  • Affiliated with Baptist Memorial Hospital-Tipton and Baptist Memorial Hospital-Memphis.

Area of expertise

1Breast Cancer
Philip E. Lammers has run 9 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER negative
PR negative
2Lung Cancer
Philip E. Lammers has run 8 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
Baptist Memorial Hospital And Cancer Center-Memphis
Image of trial facility.
Baptist Memorial Hospital And Cancer Center-Desoto

Clinical Trials Philip E. Lammers is currently running

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

More about Philip E. Lammers

Clinical Trial Related5 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Philip E. Lammers has experience with
  • Carboplatin
  • Paclitaxel
  • Pembrolizumab
  • Atezolizumab
  • Docetaxel
  • Cyclophosphamide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Philip E. Lammers specialize in?
Is Philip E. Lammers currently recruiting for clinical trials?
Are there any treatments that Philip E. Lammers has studied deeply?
What is the best way to schedule an appointment with Philip E. Lammers?
What is the office address of Philip E. Lammers?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security